Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bacil PharmaBOM:524516 -4.99%33 Forward Dividend Yield % is 0.00% as of Aug. 08, 2026. GuruFocus rates BOM:524516 with a GF Score™ of 33/100. Among 510 Drug Manufacturers companies, Bacil Pharma ranks worse than 196078.24% on this metric.
As of today (2026-08-08), the Forward Annual Dividend Yield of Bacil Pharma is 0.00%.
As of today (2026-08-08), the Trailing Annual Dividend Yield of Bacil Pharma is 0.00%.
BOM:524516's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.995 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Bacil Pharma Forward Dividend Yield % Related Terms
BOM:524516 vs ZTS: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bacil Pharma's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bacil Pharma Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bacil Pharma's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Bacil Pharma's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Bacil Pharma (BOM:524516) has a Forward Dividend Yield % of 0.00% as of Aug. 08, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bacil Pharma and its competitors. According to the industry distribution chart, Bacil Pharma ranks #999999 out of 510 companies in the Drug Manufacturers industry.
Is Bacil Pharma's Forward Dividend Yield % too high?
Bacil Pharma's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Bacil Pharma ranks #999999 out of 510 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Bacil Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Bacil Pharma's Forward Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bacil Pharma ranks #999999 out of 510 companies for Forward Dividend Yield %. This places Bacil Pharma in the lower half of its industry. The industry median Forward Dividend Yield % is 2.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.00, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Bacil Pharma and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bacil Pharma's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bacil Pharma stock overvalued right now?
Bacil Pharma (BOM:524516) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Bacil Pharma's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Bacil Pharma (BOM:524516), the current Forward Dividend Yield % is 0.00% as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bacil Pharma Ltd is an Indian-based pharmaceutical company engaged in healthcare solutions, basically in the development, manufacturing, and distribution of a range of pharmaceutical products across therapeutic segments. operating in a single segment. The product of the company includes tablets, capsules, injectables, ointments, and specialty products.
33GF Score
Get the complete analysis for BOM:524516
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524516 has been successfully added to your 
